An Interview with Andrew Newland, CEO of Angle (AIM:AGL) Plc James Faulkner: Hi Andrew. The last time we met Angle had several different projects in development, but now the company is focused solely on commercialising its patented Parsortix liquid biopsy system, which has potential applications in the diagnosis and treatment of certain cancers. Please take us…
Value investing is a famous investment style often religiously followed by both professional and amateur share pickers alike. Its core focus is upon buying shares which are trading below their so called “intrinsic” value. Trumpeted for almost 90 years now, initially by the father of value investing Benjamin Graham, the technique can help identify some…
469m shares in issue Current mid-price: 7.4p £34.7m market cap When gold showed signs of recovery, the first gold miners I looked at were those with projects not yet funded, and stalled by lack of interest from financiers. Their shares were obviously capable of strong gains if investors believed that funding would now come along.…
Unilever’s Q1 results were encouraging. The shares, as usual, look highly rated. They have understandable and legitimate technical reason to move downwards, particularly in the run up to the momentous referendum in June. These are not shares for chasing, despite the positive results, because of the high rating, which discounts almost everything positive and could…
An interview with Neil Ritson, CEO of Solo Oil Plc James Faulkner: Hi Neil. Thanks for taking the time to speak with Master Investor. Please introduce Solo Oil to our readers and explain why it is different from other Oil & Gas companies? Neil Ritson: It’s a pleasure to share some thoughts about Solo Oil,…
I thought that we were all supposed to be against the hackers, weren’t we? I mean, people who download confidential files from law firms and then use them to blackmail people indiscriminately are normally called criminals – aren’t they? Apparently not if the ultimate purpose is the international moral crusade against tax evasion with which…
What’s in a price? Barclays at 150p! The valuation ignores the significantly better prospects that arguably lie ahead. A bargain basement offer? If the UK economy is still suffering from the gargantuan world banking collapse eight years after implosion began, then so too are the banks. Barclays’ share price has been unable to resist the downward pull…
The Marks & Spencer trading statement is really encouraging despite the usual disappointment with clothing sales. This time that disappointment is qualified. The share look like a ‘buy’ and here I give my reasons for believing that. I took a gander at the share price chart to see where Marks & Spencer had got to…
I’m happy not to be in the skin of Bill Ackman, who will have to explain to investors why his Pershing Square managed to lose $1 billion in less than one one year. That will be particularly challenging because the losses are heavily concentrated in a single asset – Valeant Pharmaceuticals. The Canadian specialty pharmaceutical…
AsiaMet Resources (AIM:ARS) Well that was a spike if ever I saw one! And plenty of innocent lambs got skewered. Maybe it’s time for those responsible (an AIM market that doesn’t police misleading information and ‘research’) to get skewered themselves. I said I’d revisit ARS when its long trumpeted (by the CEO) PEA arrived. And…
